Axitinib is a medication that stops cancer cell growth by depriving the cancer cell of the nutrients and oxygen that it needs. Axitinib is used to treat advanced renal cell carcinoma (RCC), which is a type of kidney cancer that has spread within or beyond the kidney. Axitinib has been approved for the treatment of RCC as either a first treatment option or a second treatment option. It is used as a first treatment option for RCC when combined with a medication that reactivates the immune system (immunotherapy), either avelumab or pembrolizumab. If the advanced RCC starts growing again it can be used as a second treatment option where it is taken by itself. It is essential to conduct studies to assess how well the drug works and whether it has any side effects in order to understand whether it is safe to give to people. This summary reports the combined results of 5 studies and looks at how long side effects last after treatment is temporarily stopped. Researchers found that side effects generally got better in 3 days or less after people stopped taking axitinib on its own. The time it took for side effects to get better was generally shorter than for other similar drugs or combinations of axitinib and immunotherapy. The results of individual studies may vary from these 5 combined study results. Three of the 5 studies were ongoing at the time of this analysis and the final outcomes of those studies may differ from those described in this summary. The purpose of this plain language summary is to help you understand the findings from recent research. Health professionals should make treatment decisions based on all available evidence. Clinical Trial Registration: NCT00678392, NCT00920816, NCT02493751, NCT02684006, NCT02853331 (ClinicalTrials.gov).
Future oncology (London, England). 2023 Aug 01 [Epub ahead of print]
Brian I Rini, Michael B Atkins, Toni K Choueiri, Rosemary E Teresi, Brad Rosbrook, Maghull Thakur, Thomas E Hutson
Division of Hematology/Oncology, Vanderbilt University Medical Center, & Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA., Dana-Farber Cancer Institute, Boston, MA, USA., Pfizer Inc., NY, USA., Pfizer, San Diego, CA, USA., Pfizer, Sandwich, UK., Baylor Sammons Cancer Center-Texas Oncology, Dallas, TX, USA.